Nov 12, 2025 8:00 PM Eastern Standard Time On March 25, 2025, the FDA published the Warning Letter on its website, revealing that DexCom had "adulterated†its G6 and G7 glucose monitors by "modifying the G6 and G7 sensors†without prior regulatory approval, thereby subjecting the devices to "larger inaccuracies†that "cause higher risks for users who rely on the sensors to dose insulin or make other diabetes treatment decisions.†On this news, the price of DexCom shares declined by $1.77 per share, or approxima ...